The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
Public ClinicalTrials.gov record NCT05203172. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
ENCORAFENIB/BINIMETINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM ENCORAFENIB/BINIMETINIB CLINICAL STUDIES
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this clinical trial (called the FLOTILLA study) is to give continued access to the study medicines, as well as safety follow-up, for participants in prior clinical trials of encorafenib and/or binimetinib. All participants who took part in earlier encorafenib and/or binimetinib studies may participate in the FLOTILLA study if they are still benefiting from the use of the study medicines. This will be determined by the study doctor. People may not participate in the FLOTILLA study if they were not enrolled in a prior study of encorafenib or binimetinib. Participants who had enrolled but had stopped receiving the study treatment in a prior study cannot be enrolled in this study. Participants in the FLOTILLA study will receive study treatment at the same dose and frequency as in their prior study, for up to about 5 years.
Study identification
- NCT ID
- NCT05203172
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 210 participants
Conditions and interventions
Conditions
Interventions
- Binimetinib Drug
- Encorafenib Drug
- Vemurafenib Drug
- Ribociclib Drug
- Cetuximab Biological
- Pembrolizumab Biological
- Nivolumab Biological
- 5-Fluorouracil Drug
- Leucovorin Drug
- Oxaliplatin Drug
- Irinotecan Drug
- Capecitabine Drug
- Bevacizumab Biological
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 5, 2022 (Actual)
- Primary completion
- Jul 31, 2029 (Estimated)
- Completion
- Jun 30, 2032 (Estimated)
- Last update posted
- Oct 19, 2026
2022 – 2032
United States locations
- U.S. sites
- 18
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| St. Joseph's Hospital and Medical Center | Phoenix | Arizona | 85004 | Recruiting |
| St. Joseph's Hospital and Medical Center | Phoenix | Arizona | 85013 | Recruiting |
| Emory University Hospital Midtown | Atlanta | Georgia | 30308 | Recruiting |
| Emory University Hospital | Atlanta | Georgia | 30322 | Recruiting |
| Investigational Drug Service Emory University Clinic | Atlanta | Georgia | 30322 | Recruiting |
| Winship Cancer Institute of Emory University | Atlanta | Georgia | 30322 | Recruiting |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | Recruiting |
| HealthPartners Cancer Research Center | Saint Paul | Minnesota | 55101 | Recruiting |
| Regions Hospital Pharmacy | Saint Paul | Minnesota | 55101 | Recruiting |
| Siteman Cancer Center | St Louis | Missouri | 63108 | Recruiting |
| Barnes-Jewish Hospital | St Louis | Missouri | 63110 | Recruiting |
| Washington University School of Medicine | St Louis | Missouri | 63110 | Recruiting |
| Washington University | St Louis | Missouri | 63110 | Recruiting |
| MSK Basking Ridge | Basking Ridge | New Jersey | 07920 | Active, not recruiting |
| Rockefeller Outpatient Pavilion (53rd Street) | New York | New York | 10022 | Active, not recruiting |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | Active, not recruiting |
| Duke Cancer Center | Durham | North Carolina | 27710 | Recruiting |
| Investigational Chemotherapy Service | Durham | North Carolina | 27710 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 59 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05203172, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 19, 2026 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05203172 live on ClinicalTrials.gov.